<DOC>
	<DOCNO>NCT00485758</DOCNO>
	<brief_summary>A study ass efficacy tolerability ER ( Extended Release ) niacin/laropiprant versus placebo Type 2 Diabetes Mellitus patient .</brief_summary>
	<brief_title>Extended Niacin/Laropiprant Patients With Type 2 Diabetes ( 0524A-069 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Patients age 18 80 year Type 2 Diabetes stable dose antidiabetic medication least 3 month Patients take Cholestin , niacin ( &gt; 50 mg/day ) , fibrate therapy , hormonal contraceptive , intermittent Hormone Replacement Therapy , certain corticosteroid Patients follow condition : active liver disease kidney disease , poorly control high blood pressure , active peptic ulcer , heart blood disease Patients abnormal laboratory result blood test give start study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>